These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33479762)

  • 1. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort.
    Tamura K; Osawa T; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Sugimoto M; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Komiyama M; Tanaka K; Yokomizo A; Kohei N; Shinohara N; Miyake H;
    Jpn J Clin Oncol; 2021 Apr; 51(5):810-818. PubMed ID: 33479762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of the ACL (albumin, C-reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first-line targeted therapy.
    Tamura K; Matsushita Y; Watanabe H; Motoyama D; Ito T; Sugiyama T; Otsuka A; Miyake H
    Urol Oncol; 2020 Jan; 38(1):6.e9-6.e16. PubMed ID: 31400935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
    Osawa T; Kojima T; Hara T; Sugimoto M; Eto M; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Miyauchi Y; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Tamura K; Komiyama M; Goto T; Yokomizo A; Kohei N; Kashiwagi A; Murakami M; Sazuka T; Yasumoto H; Iwamoto H; Mitsuzuka K; Morooka D; Shimazui T; Yamamoto Y; Ikeshiro S; Nakagomi H; Morita K; Tomida R; Mochizuki T; Inoue T; Kitamura H; Yamada S; Ito YM; Murai S; Nishiyama H; Shinohara N;
    Cancer Sci; 2020 Jul; 111(7):2460-2471. PubMed ID: 32402135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.
    Tamura K; Ando R; Takahara K; Ito T; Kanao K; Yasui T; Shiroki R; Miyake H
    Urol Oncol; 2021 Jan; 39(1):78.e1-78.e8. PubMed ID: 32958444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era?
    Shinohara N; Abe T; Mochizuki T; Kashiwagi A; Kanagawa K; Maruyama S; Sazawa A; Oba K; Nonomura K
    Urol Oncol; 2013 Oct; 31(7):1276-82. PubMed ID: 21956045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study.
    Konishi S; Hatakeyama S; Numakura K; Narita S; Inoue T; Saito M; Tokui N; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Narita S; Kawaguchi T; Habuchi T; Ohyama C
    Clin Genitourin Cancer; 2019 Oct; 17(5):e1080-e1089. PubMed ID: 31416753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma.
    Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Hamano I; Fujita N; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
    Int J Urol; 2019 Oct; 26(10):992-998. PubMed ID: 31342557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma.
    Yamamoto Y; Matsuyama H; Matsumoto H; Sakano S; Fuji N; Oba K; Yamamoto M; Kamiryo Y; Hiragino T; Nagao K; Takai K; Aoki A
    Jpn J Clin Oncol; 2020 Feb; 50(2):214-220. PubMed ID: 31755525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma.
    Kameda T; Takayama T; Sugihara T; Takeshima S; Yamazaki M; Komatsubara M; Kamei J; Fujisaki A; Ando S; Kurokawa S; Fujimura T
    Asia Pac J Clin Oncol; 2020 Aug; 16(4):241-246. PubMed ID: 32129940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology.
    Numakura K; Kobayashi M; Muto Y; Sekine Y; Takahashi M; Kashima S; Yamamoto R; Koizumi A; Nara T; Saito M; Narita S; Nanjyo H; Habuchi T
    Sci Rep; 2020 Nov; 10(1):20089. PubMed ID: 33208816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
    Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
    Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
    Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
    Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma.
    Ueda K; Suekane S; Hirano T; Ogasawara N; Chikui K; Uemura K; Nakiri M; Nishihara K; Matsuo M; Igawa T
    Anticancer Res; 2018 Sep; 38(9):5387-5392. PubMed ID: 30194193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan.
    Miyake H; Harada KI; Ozono S; Fujisawa M
    Clin Genitourin Cancer; 2017 Feb; 15(1):122-128. PubMed ID: 27473522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
    Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
    Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.
    Kawai Y; Osawa T; Kobayashi K; Inoue R; Yamamoto Y; Matsumoto H; Nagao K; Hara T; Sakano S; Nagamori S; Matsuyama H
    Asian Pac J Cancer Prev; 2015; 16(14):5687-90. PubMed ID: 26320436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice.
    Kamba T; Yamasaki T; Teramukai S; Shibasaki N; Arakaki R; Sakamoto H; Matsui Y; Okubo K; Yoshimura K; Ogawa O
    Int J Clin Oncol; 2014; 19(3):505-15. PubMed ID: 23813043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma.
    Zhou L; Liu Y; Mo J; Cui C; Chi Z; Si L; Kong Y; Yan X; Li S; Wu X; Li J; Xu H; Cao D; Guo J; Sheng X
    Urol Oncol; 2022 Aug; 40(8):385.e1-385.e8. PubMed ID: 35773144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.